A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me’ signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in eliminatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Barry, Liedtke, Michaela, Khouri, Jack, Rifkin, Robert, Gandhi, Mitul D, Kin, Andrew, Levy, Moshe Y, Silbermann, Rebecca, Cottini, Francesca, Sborov, Douglas W, Sandhu, Irwindeep, Villarreal, Lyssa, Murphy, Michael, Gu, Lin, Chen, Ann, Rajakumaraswamy, Nishanthan, Usmani, Saad Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463212/
https://www.ncbi.nlm.nih.gov/pubmed/36779512
http://dx.doi.org/10.2217/fon-2022-0975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463212/
https://www.ncbi.nlm.nih.gov/pubmed/36779512
http://dx.doi.org/10.2217/fon-2022-0975

Ejemplares similares